Ratings Probiotec Limited

Equities

PBP

AU000000PBP7

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
2.83 ^AUD	-0.35%		-0.35%	-2.41%

Feb. 27	Probiotec Limited Declares Interim Dividend, Payable on 15 March 2024	CI
Feb. 27	Probiotec Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.

Weaknesses

For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PROBIOTEC LIMITED	-2.41%	150M	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes